WO2022113530A1 - ポリ(3-ヒドロキシアルカノエート)の製造方法 - Google Patents
ポリ(3-ヒドロキシアルカノエート)の製造方法 Download PDFInfo
- Publication number
- WO2022113530A1 WO2022113530A1 PCT/JP2021/036938 JP2021036938W WO2022113530A1 WO 2022113530 A1 WO2022113530 A1 WO 2022113530A1 JP 2021036938 W JP2021036938 W JP 2021036938W WO 2022113530 A1 WO2022113530 A1 WO 2022113530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- p3ha
- molecular weight
- poly
- average molecular
- powder
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 60
- 229920000739 poly(3-hydroxycarboxylic acid) polymer Polymers 0.000 title claims description 30
- 238000011282 treatment Methods 0.000 claims abstract description 70
- 102000004190 Enzymes Human genes 0.000 claims abstract description 51
- 108090000790 Enzymes Proteins 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 239000000843 powder Substances 0.000 claims description 90
- 239000000243 solution Substances 0.000 claims description 74
- 229940088598 enzyme Drugs 0.000 claims description 49
- 108091005804 Peptidases Proteins 0.000 claims description 36
- 102000035195 Peptidases Human genes 0.000 claims description 36
- 239000007864 aqueous solution Substances 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 22
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 18
- 230000014759 maintenance of location Effects 0.000 claims description 16
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 108010014251 Muramidase Proteins 0.000 claims description 11
- 102000016943 Muramidase Human genes 0.000 claims description 11
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 11
- 239000004325 lysozyme Substances 0.000 claims description 10
- 229960000274 lysozyme Drugs 0.000 claims description 10
- 235000010335 lysozyme Nutrition 0.000 claims description 10
- 108010056079 Subtilisins Proteins 0.000 claims description 8
- 102000005158 Subtilisins Human genes 0.000 claims description 8
- 230000035484 reaction time Effects 0.000 claims description 6
- 230000001420 bacteriolytic effect Effects 0.000 claims description 4
- 229920001020 poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) Polymers 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 55
- 239000012535 impurity Substances 0.000 abstract description 23
- 230000000813 microbial effect Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000002270 dispersing agent Substances 0.000 description 40
- 239000007900 aqueous suspension Substances 0.000 description 38
- 125000002947 alkylene group Chemical group 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 229920001451 polypropylene glycol Polymers 0.000 description 16
- 239000006228 supernatant Substances 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- -1 catepsin D Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 9
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 239000008235 industrial water Substances 0.000 description 8
- HPMGFDVTYHWBAG-UHFFFAOYSA-N 3-hydroxyhexanoic acid Chemical compound CCCC(O)CC(O)=O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000003513 alkali Substances 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000007334 copolymerization reaction Methods 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 5
- 108010013639 Peptidoglycan Proteins 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 238000001694 spray drying Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007514 bases Chemical class 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 229920001013 poly(3-hydroxybutyrate-co-4-hydroxybutyrate) Polymers 0.000 description 4
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 description 4
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 3
- 241000607534 Aeromonas Species 0.000 description 3
- 241000588986 Alcaligenes Species 0.000 description 3
- 241001528480 Cupriavidus Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 241000589151 Azotobacter Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001528539 Cupriavidus necator Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000232299 Ralstonia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920000704 biodegradable plastic Polymers 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052762 osmium Inorganic materials 0.000 description 2
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000193033 Azohydromonas lata Species 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005325 alkali earth metal hydroxides Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 238000012661 block copolymerization Methods 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000003898 horticulture Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002667 nucleating agent Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
- C12P7/625—Polyesters of hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/88—Post-polymerisation treatment
- C08G63/89—Recovery of the polymer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21062—Subtilisin (3.4.21.62)
Definitions
- the present invention relates to a method for producing poly (3-hydroxyalkanoate).
- P3HA poly (3-hydroxyalkanoate)
- Patent Document 1 describes a method in which a cell containing P3HA is enzymatically treated and then treated with an alkaline aqueous solution.
- Patent Document 2 describes a method for treating a bacterial cell containing P3HA with an alkaline aqueous solution.
- an object of the present invention is to provide a method for producing P3HA from cells containing P3HA in high yield and with reduced impurities (particularly, residual protein).
- the present inventors have subjected to alkaline treatment of the cells containing P3HA before crushing (before enzyme treatment) and after crushing (after enzyme treatment).
- the present invention has been completed for the first time by finding that P3HA can be obtained in high yield and with reduced impurities (particularly, residual protein) by adjusting the molecular weight of P3HA.
- one aspect of the present invention is a method for producing a poly (3-hydroxyalkanoate) having a weight average molecular weight of 100,000 to 700,000, and (a) a cell containing the poly (3-hydroxyalkanoate).
- the weight average molecular weight is 100,000 to 600,000, the residual protein amount is 2000 ppm or less, the particle surface is non-porous, and it is represented by the following formula (1).
- Weight average molecular weight retention rate (%) (Weight average molecular weight of P3HA after heating at 160 ° C for 20 minutes / Weight average molecular weight of P3HA before heating at 160 ° C for 20 minutes) ⁇ 100 ... (1)
- the method for producing a poly (3-hydroxy alkanoate) according to an embodiment of the present invention is a poly (3-hydroxy alkanoate) having a weight average molecular weight of 100,000 to 700,000.
- a method for producing (ate) wherein (a) an alkaline aqueous solution is added to a culture solution containing cells containing poly (3-hydroxyalkanoate) to adjust the pH to 8.0 to 12.0. (B) An enzyme is added to the culture solution obtained in the step (a) to treat the cells with an enzyme, and (c) an alkaline aqueous solution is added to the culture solution obtained in the step (b). It is characterized by including a step of adjusting the pH to 10.0 to 12.0.
- the present inventor has found that when an attempt is made to produce P3HA from a cell containing P3HA by the method described in Patent Document 1, there arises a problem that the yield of P3HA decreases. In particular, it has been found that the yield of P3HA becomes extremely poor when producing P3HA having a low molecular weight. Further, the present inventor tried to produce P3HA from cells containing P3HA by the method described in Patent Document 2, and found that the obtained P3HA contained a large amount of impurities (particularly, residual protein). .. When processed using such P3HA, foreign matter is generated in the product, which causes a problem that the quality is deteriorated.
- the present inventor treated the cells with an alkali before crushing the cells (before enzyme treatment) and after crushing (after enzyme treatment) to adjust the molecular weight of P3HA.
- an alkali before crushing the cells
- after crushing after enzyme treatment
- P3HA can be obtained in high yield and with reduced impurities (particularly, residual protein).
- "after crushing the cells” may be after the enzyme treatment step of the step (b) described later, and is intended to include the time of crushing the cells.
- the present inventor has found for the first time that the P3HA obtained by the above production method has the following characteristics: -Excellent thermal stability. -From the viewpoint of molecular weight distribution, it should contain a large amount of P3HA of the same molecular weight (monodispersity). -When low molecular weight P3HA is produced, the surface of the obtained P3HA powder is non-porous.
- the present inventor presumes as follows as a factor for obtaining high-yield P3HA by this production method. That is, in the conventional method (for example, the method described in Patent Document 1), since the molecular weight is adjusted after P3HA is crystallized, the molecular weight of the crystallized portion of P3HA cannot be sufficiently adjusted, and as a result, P3HA is adjusted. Only the ends of the cells are hydrolyzed to generate small, unrecoverable molecules. On the other hand, in this production method, P3HA in an amorphous state is randomly hydrolyzed by adjusting the molecular weight before crushing the cells. As a result, the generation of unrecoverable small molecules is suppressed, and a high yield can be achieved.
- the present inventor speculates as follows as a factor for obtaining P3HA with reduced impurities (particularly, residual protein) by this production method. That is, in the method described in the conventional method (for example, Patent Document 2), washing with a surfactant is performed immediately after crushing the cells, so that the residual protein derived from the cells is not sufficiently removed. On the other hand, in this production method, impurities such as proteins derived from cells are dispersed and dissolved by performing alkaline treatment after crushing the cells, so that P3HA having few impurities can be produced.
- This production method is a method for producing P3HA of poly (3-hydroxyalkanoate) having a weight average molecular weight of 100,000 to 700,000, which comprises the following steps (a) to (c).
- the manufacturing method may appropriately include steps (a'), (c'), (d), (e), (f) and the like shown below.
- molecular weight means “weight average molecular weight” unless otherwise specified.
- low molecular weight P3HA is intended to be P3HA having a weight average molecular weight of 300,000 or less.
- the P3HA produced by this production method is preferably a low molecular weight P3HA.
- the step (a) is a step of adding an alkaline aqueous solution to the culture solution containing the cells containing P3HA (also referred to as “alkaline treatment”) to adjust the pH to 8.0 to 12.0. That is, it can be said that it is a step of hydrolyzing P3HA and adjusting the molecular weight of P3HA by adjusting the pH to 8.0 to 12.0. According to this step, in the cells containing P3HA, the molecular weight of the P3HA can be adjusted in the cells (in other words, in a state where the P3HA is not crystallized (amorphous)).
- the step (a) is a step of maintaining the culture solution containing the cells containing P3HA at a pH of 8.0 to 12.0 for a certain period of time. Further, it can be said that the step (a) is a molecular weight adjusting step.
- P3HA means the following formula (2) :. [-O-CHR-CH 2 -CO-] (2) (In the formula, R is an alkyl group represented by C n H 2n + 1 , and n is an integer of 1 to 15) is intended to be a general term for copolymers consisting of one or more units represented by. ..
- P3HA is not particularly limited as long as it is included in the above formula (2).
- P3HA may be a poly (3-hydroxybutyrate) having only 3-hydroxybutyrate as a repeating unit, or 3-hydroxybutyrate and another hydroxyalkanoate. It may be a copolymer.
- P3HA may be a mixture of a homopolymer and one or more copolymers, or may be a mixture of two or more copolymers.
- the type of copolymerization is not particularly limited, and may be random copolymerization, alternate copolymerization, block copolymerization, graft copolymerization, or the like.
- examples of P3HA include poly (3-hydroxybutyrate) (P3HB), poly (3-hydroxybutyrate-co-3-hydroxypropionate) (P3HB3HP), and poly (3).
- P3HB3HH poly (3-hydroxybutyrate-co-3-hydroxyhexanoate)
- P3HB3HV poly (3-hydroxybutyrate-co-4- (Hydroxybutyrate)
- P3HB4HB poly (3-hydroxybutyrate-co-3-hydroxyoctanoate)
- P3HB3HO poly (3-hydroxybutyrate-co-3-hydroxyoctanoate)
- P3HB3HOD Poly (3-hydroxybutyrate-co-3-hydroxydecanoate)
- P3HB3HD Poly (3-hydroxybutyrate-co-3-hydroxydecanoate)
- P3HB3HV3HH Poly (3-hydroxybutyrate-co-3-hydroxyvariate-co-3-hydroxyhexanoate)
- P3HB3HH, P3HB4HB, and P3HB3HP are preferable.
- P3HB and P3HB3HV are preferable, and P3HB3HH and P3HB4HB are particularly preferable because they are industrially easy to produce.
- the composition ratio of the copolymerization component of P3HA is within the above range, P3HA having excellent processability can be provided.
- the weight average molecular weight (hereinafter, also referred to as “initial molecular weight”) of P3HA before adjusting the molecular weight (that is, before adding the alkaline aqueous solution) is not particularly limited, but is, for example, 3 million or less. Yes, it is preferably 2.8 million or less, and more preferably 2.5 million or less.
- the lower limit of the initial molecular weight of P3HA is not particularly limited, but may be, for example, 400,000 or more.
- the initial molecular weight of P3HA is measured by the method described in Examples.
- the term "cells containing P3HA” is intended to be a microorganism that produces P3HA. That is, in one embodiment of the invention, P3HA is produced by microorganisms.
- the microorganism used in this production method is not particularly limited as long as it is a microorganism capable of producing P3HA in cells. For example, microorganisms isolated from nature, microorganisms deposited in a deposit agency for strains (for example, IFO, ATCC, etc.), or mutants or transformants that can be prepared from them can be used.
- the genus Cupriavidus the genus Alcaligenes, the genus Ralstonia, the genus Pseudomonas, the genus Bacillus, the genus Azotobacter, the genus Azotobacter, the genus Nocardia.
- bacteria of the genus Aeromonas include bacteria of the genus Aeromonas.
- microorganisms belonging to the genus Aeromonas, Alcaligenes, Ralstonia, or Cupriavidus are preferable.
- the target P3HA synthase gene and / or a mutant thereof can be applied to the microorganism.
- the transformant obtained by introduction can also be used.
- the gene for the P3HA synthase used for producing such a transformant is not particularly limited, but the gene for the P3HA synthase derived from Aeromonas cavier is preferable.
- the cells containing P3HA are preferably inactivated.
- the method of inactivation is not particularly limited, and examples thereof include a method of heating and stirring a culture solution containing cells containing P3HA at 70 ° C to 80 ° C for 8 hours.
- the alkaline aqueous solution is an aqueous solution containing a basic compound.
- the basic compound contained in the alkaline aqueous solution is not particularly limited, and for example, an alkali metal such as sodium hydroxide and potassium hydroxide or an alkali earth metal hydroxide; a metal carbonate such as sodium carbonate and potassium carbonate; Examples thereof include metal phosphates such as sodium phosphate, potassium phosphate, sodium hydrogen phosphate, potassium hydrogen phosphate and the like, or metal hydrogen phosphate salts.
- the basic compound contained in the alkaline aqueous solution is preferably an alkali metal hydroxide or an alkaline earth metal hydroxide, and more preferably sodium hydroxide.
- the basic compound one kind may be used alone, or two or more kinds may be used in combination.
- the pH is preferably adjusted to 8.0 to 12.0, more preferably 8.2 to 11.5, and 8.4 by adding an alkaline aqueous solution. It is more preferable to adjust to ⁇ 11.5.
- the reaction time (in other words, the time for adjusting and maintaining the pH to 8.0 to 12.0) in the step (a) is, for example, 4 hours to 30 hours, preferably 8 hours to 20 hours.
- the reaction time in the step (a) is within the above range, the molecular weight of P3HA in the cells can be adjusted to a suitable range, and excessive reduction of the molecular weight of P3HA can be prevented.
- the temperature in the step (a) is preferably less than 100 ° C, more preferably less than 80 ° C.
- the lower limit is not particularly limited, but is preferably 50 ° C. or higher, for example.
- the yield of P3HA is calculated based on the following formulas (3) and (4):
- P3HA content (g / g) (weight of dried product (g) / weight of culture solution (g)) ...
- Yield of P3HA (%) (P3HA content of culture solution after molecular weight adjustment / P3HA content of culture solution before molecular weight adjustment) ⁇ 100 ⁇ (solid content concentration (%) of culture solution before molecular weight adjustment / after molecular weight adjustment Solid content concentration (%) of the culture solution of
- the various parameters in the above formulas (3) and (4) are measured by the method described in Examples.
- This manufacturing method includes a molecular weight adjustment step (alkali treatment step) at least twice.
- the "P3HA content of the culture solution before the molecular weight adjustment" in the formula (4) is intended to be the P3HA content of the culture solution before the first molecular weight adjustment is performed, and the "P3HA content of the culture solution after the molecular weight adjustment" is The P3HA content of the culture is intended after the final molecular weight adjustment has been made.
- P3HA content of the culture solution before molecular weight adjustment and “P3HA content of the culture solution after molecular weight adjustment” are values measured by the method described in Examples.
- the yield of P3HA is 95% or more, preferably 95.3% or more, and more preferably 95.5% or more from the viewpoint of productivity.
- the higher the yield of P3HA, the better, and the upper limit is not particularly limited, but for example, it is 99%, preferably 99.5%, and most preferably 100%.
- the step (b) is a step of adding an enzyme to the culture solution obtained in the step (a) to carry out the enzyme treatment of the cells. According to this step, P3HA can be efficiently recovered from the cells by destroying and removing impurities (cell wall, protein, etc.) derived from the cells.
- the enzymatic treatment of step (b) can be an alkaline proteolytic enzyme treatment and / or a lytic enzyme treatment.
- the alkaline proteolytic enzyme treatment and the lytic enzyme treatment are preferably performed at least once, and if necessary, the alkaline proteolytic enzyme treatment and / or the lytic enzyme treatment may be performed twice or more.
- the order of performing the alkaline proteolytic enzyme treatment and / or the lytic enzyme treatment is not particularly limited.
- the enzyme treatment in step (b) is preferably performed in the order of alkaline proteolytic enzyme treatment, lytic enzyme treatment, and alkaline proteolytic enzyme treatment.
- the enzymatic treatment in the step (b) in the above order, it is not necessary to use sulfuric acid or the like for adjusting the pH of the culture solution in this production method. That is, P3HA can be produced without using sulfuric acid or the like, which is a corrosive liquid for equipment.
- the reason why the above order is preferable is that the present inventor lowers the pH in the culture solution to near neutral by the first treatment with an alkaline proteolytic enzyme, and as a result, it is not necessary to add sulfuric acid or the like for pH adjustment. I'm guessing there is.
- step (b) when performing enzyme treatment (for example, alkaline proteolytic enzyme treatment and lytic enzyme treatment), the pH and temperature of the culture solution are adjusted according to the optimum pH and temperature of the enzyme to be used. It is preferable to do so.
- the method for adjusting the pH and temperature of the culture solution is not particularly limited, and known methods can be used.
- alkaline proteolytic enzyme treatment As used herein, the term "alkaline proteolytic enzyme” is intended to be a proteolytic enzyme having an activity of degrading a protein in an alkaline environment (for example, in a solution having a pH of 8.5).
- alkaline proteolytic enzyme treatment is intended to be a step of adding the alkaline proteolytic enzyme to the culture solution and enzymatically treating the cells.
- the alkaline proteolytic enzyme is not particularly limited as long as it has an activity of degrading proteins in an alkaline environment, for example, serine-specific proteolytic enzymes (eg, subtilisin, chymotrypsin, trypsin), cysteine.
- serine-specific proteolytic enzymes eg, subtilisin, chymotrypsin, trypsin
- Specific proteolytic enzymes eg papaine, promeline, catepsin
- aspartate-specific proteolytic enzymes eg pepsin, catepsin D, HIV protease
- Serine-specific proteolytic enzymes, especially subtilisin (eg, alcalase) are preferred from the viewpoint of economic advantage.
- subtilisin eg, alcalase
- alkaline proteolytic enzyme for example, "Alkalase 2.5L” manufactured by Novozyme Co., Ltd .; “Protin SD-AY10” and “Protease P” Amano "3SD” manufactured by Amano Enzyme Co., Ltd .; “Multifect PR6L” and “Optimase PR89L” manufactured by Japan Co., Ltd .; “Sumiteam MP” manufactured by Shin Nihon Kagaku Kogyo Co., Ltd .; “Delbolase” manufactured by DSM Japan Co., Ltd .; , “Bioplase SP-20FG” and “Bioplase SP-4FG”; "Orientase 22BF” manufactured by HBI Co., Ltd .; “Aloase XA-10” manufactured by Yakult Pharmaceutical Co., Ltd. and the like.
- the optimum pH of the alkaline proteolytic enzyme is not particularly limited as long as the alkaline proteolytic enzyme has activity in an alkaline environment, but is, for example, 8.0 to 14.0, preferably 8.0 to 14.0. It is 8.0 to 12.0, more preferably 8.0 to 10.0, still more preferably 8.0 to 9.0, and most preferably 8.5.
- the optimum temperature of the alkaline proteolytic enzyme is not particularly limited, but from the viewpoint that excessive heating is not required and thermal change (pyrolysis) of P3HA can be prevented. It is preferably 60 ° C. or lower, and more preferably 50 ° C. or lower.
- the lower limit of the optimum temperature is not particularly limited, but is preferably room temperature (for example, 25 ° C.) or higher from the viewpoint of not requiring an excessive cooling operation and being economical.
- the alkaline proteolytic enzyme treatment is a step of adding a lytic enzyme to the culture solution and enzymatically treating the cells.
- lytic enzyme is intended to be an enzyme having an activity of degrading (bacteriolytic) the cell wall (for example, peptidoglycan) of a bacterial cell.
- the lytic enzyme is not particularly limited, and examples thereof include lysozyme, labia, ⁇ -N-acetylglucosaminidase, endolysine, and autolysine. Lysozyme is preferred from the perspective of being economically advantageous. One of these types may be used alone, or two or more types may be used in combination.
- lytic enzyme a commercially available product can also be used, and examples thereof include “lysozyme” and “achromopeptidase” manufactured by Wako Pure Chemical Industries, Ltd.
- the optimum pH of the lytic enzyme is not particularly limited as long as the lytic enzyme has cell wall degrading activity, but is, for example, 5.0 to 11.0, preferably 6.0 to 9. It is 0.0, more preferably 6.0 to 8.0.
- the optimum temperature of the lytic enzyme is not particularly limited, but from the viewpoint that excessive heating is not required and thermal change (pyrolysis) of P3HA can be prevented, the temperature is 60 ° C. or lower. Is preferable, and 50 ° C. or lower is even more preferable.
- the lower limit of the optimum temperature is not particularly limited, but it is preferably room temperature (for example, 25 ° C.) or higher from the viewpoint of being economical without the need for an excessive cooling operation.
- the enzymatic treatment of step (b) can be performed by a combination of lysozyme and alcalase.
- the enzyme treatment time in the step (b) may vary depending on the type of enzyme, pH, temperature and other conditions, but is, for example, 1 hour to 8 hours, preferably 2 hours to 6 hours.
- the manufacturing method may further include step (a') between steps (a) and (b).
- the step (a') is a step of adjusting the pH of the culture solution obtained in the step (a) to 6.0 to 8.0
- the enzyme treatment in the step (b) is a lytic enzyme treatment and a lytic enzyme treatment. It involves performing alkaline proteolytic enzyme treatment in this order.
- the method for adjusting the pH is not particularly limited, and examples thereof include a method of adding an acid to the culture solution.
- the acid is not particularly limited, and may be either an organic acid or an inorganic acid, and may or may not be volatile. More specifically, as the acid, for example, sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid and the like can be used.
- the step (c) is a step of adding an alkaline aqueous solution to the culture solution obtained in the step (b) to adjust the pH to 10.0 to 12.0. According to this step, the molecular weight of P3HA can be adjusted to a smaller value, and when the cells are disrupted, impurities (nucleic acid, protein, etc.) derived from the cells are dispersed and dissolved to obtain high-purity P3HA. Can be separated from the body.
- the step (c) can also be said to be an alkaline cleaning step.
- the pH is preferably adjusted to 10.0 to 12.0, more preferably 10.2 to 11.8 by adding an alkaline aqueous solution, 10.4 to 11 It is more preferable to adjust to 6.6.
- the pH is preferably adjusted to 10.0 or higher, the P3HA in the cells can be further adjusted to a lower molecular weight. Further, by adjusting the pH to 12.0 or less, it is possible to prevent excessive reduction in the molecular weight of P3HA.
- the reaction time in the step (c) (in other words, the time for adjusting and maintaining the pH at 10.0 to 12.0) is, for example, 1 hour to 12 hours, preferably 1 hour to 6 hours.
- the reaction time in the step (c) is within the above range, the molecular weight of P3HA in the cells can be adjusted to a suitable range, and excessive reduction of the molecular weight of P3HA can be prevented.
- the manufacturing method may further include step (c') after step (c). It can be said that the step (c') is a surfactant treatment step.
- the step (c') is a step of adding a surfactant to the culture solution obtained in the step (c). According to this step, impurities contained in the cells, particularly cell membranes, can be efficiently treated and more impurities derived from the cells can be removed, so that higher purity P3HA can be separated from the cells. can.
- the surfactant is not particularly limited, and examples thereof include anionic surfactants, cationic surfactants, amphoteric surfactants, and nonionic surfactants.
- anionic surface activity is preferable from the viewpoint of high ability to remove cell membranes.
- One of these types may be used alone, or two or more types may be used in combination.
- anionic surfactant examples include alkyl sulfates, alkylbenzene sulfonates, alkyl sulfates, alkenyl sulfates, alkyl ether sulfates, alkenyl ether sulfates, ⁇ -olefin sulfonates and ⁇ -.
- examples thereof include sulfo fatty acid salts, esters of ⁇ -sulfo fatty acid salts, alkyl ether carboxylates, alkenyl ether carboxylates, amino acid-type surfactants, N-acyl amino acid-type surfactants and the like.
- an alkyl sulfate ester salt is preferable, and sodium dodecyl sulfate (SDS) is particularly preferable from the viewpoint of high ability to remove cell membranes and low cost.
- SDS sodium dodecyl sulfate
- One of these types may be used alone, or two or more types may be used in combination.
- the amount of the surfactant to be added is not particularly limited, and is, for example, 0.1 to 5.0% by weight and 0.3 to 2.5% by weight with respect to the culture solution. Is preferable.
- the step (c') may be performed before the step (c) or at the same time as the step (c). That is, the surfactant may be added before or at the same time as the addition of the alkaline aqueous solution to the culture solution. Further, the addition of the surfactant can be performed before the step (a) or at the same time as the step (a).
- the manufacturing method may further comprise step (d).
- Step (d) is a step of centrifuging the culture solution obtained in the step (c) and removing the supernatant to obtain a P3HA aqueous suspension enriched with P3HA. That is, it is a step of removing impurities from P3HA separated from the bacterial cells, and concentrating and purifying the cells. It can be said that the step (d) is a centrifugation step.
- the method for centrifuging the culture solution is not particularly limited, and a known method can be used.
- step (d) it is preferable to repeat the steps of centrifuging the culture solution, removing the supernatant, adding the solution to the sediment, and centrifuging and removing the supernatant again.
- the solution to be added after removing the supernatant is preferably an alkaline aqueous solution adjusted to the same pH as the culture solution.
- the solution is preferably the same as the alkaline aqueous solution used in the step (c).
- the amount of impurities remaining in the final product is generally determined by the step (d), it is preferable to reduce these impurities as much as possible.
- impurities may be mixed as long as the physical properties of the final product are not impaired, but when high-purity P3HA is required for medical applications, etc., impurities can be reduced as much as possible. preferable.
- the amount of protein in the P3HA aqueous suspension can be mentioned.
- the amount of protein in the P3HA aqueous suspension is not particularly limited as long as the amount of residual protein in the P3HA powder described later can be achieved.
- the amount of the protein is preferably 3000 ppm or less, more preferably 2500 ppm or less, still more preferably 2000 ppm or less per P3HA weight in the P3HA aqueous suspension.
- the solvent constituting the P3HA aqueous suspension (“solvent” is also referred to as “aqueous medium”) is not particularly limited, and may be water or a mixed solvent of water and an organic solvent. May be good. Further, in the mixed solvent, the concentration of the organic solvent is not particularly limited as long as it is equal to or less than the solubility of the organic solvent used in water.
- the organic solvent is not particularly limited, and for example, alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, iso-butanol, pentanol, hexanol, and heptanol; acetone and methyl ethyl ketone.
- Ketones such as; ethers such as tetrahydrofuran and dioxane; nitriles such as acetonitrile and propionitrile; amides such as dimethylformamide and acetamide; dimethylsulfoxide, pyridine, piperidine and the like.
- methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, iso-butanol, acetone, methyl ethyl ketone, tetrahydrofuran, dioxane, acetonitrile, propionitrile and the like are preferable because they are easy to remove.
- methanol, ethanol, 1-propanol, 2-propanol, butanol, acetone and the like are more preferable because they are easily available. Further, methanol, ethanol and acetone are particularly preferable.
- the content of water in the aqueous medium constituting the P3HA aqueous suspension is preferably 5% by weight or more, more preferably 10% by weight or more, still more preferably 30% by weight or more, and particularly preferably 30% by weight or more. , 50% by weight or more.
- the P3HA aqueous suspension in step (d) may contain other solvents, bacterial cell-derived components, compounds generated during purification, etc., as long as the essence of the present invention is not impaired.
- the manufacturing method may further comprise step (e).
- Step (e) is a step of adding a dispersant to the P3HA aqueous suspension obtained in the step (d) and preparing a P3HA aqueous suspension having a pH of 7 or less. It can be said that the step (e) is a pH adjusting step.
- the step (e) preferably includes the following steps (e1) and step (e2). -Step (e1): Step of adding a dispersant to the P3HA aqueous suspension-Step (e2): Step of adjusting the pH of the P3HA aqueous suspension to 7 or less Step (e1) and step (e2) are carried out.
- the order is not particularly limited, but from the viewpoint of suppressing the aggregation of P3HA in the step (e2) and obtaining an aqueous suspension having more excellent dispersion stability of P3HA, the step (e2) is performed after the step (e1). It is preferable to carry out.
- the dispersant to be added in the step (e) is not particularly limited, and examples thereof include polyvinyl alcohol (PVA) -based dispersants, alkylene oxide-based dispersants, cellulose-based dispersants, and alcohol-based dispersants.
- PVA polyvinyl alcohol
- the polyvinyl alcohol-based dispersant and the alkylene oxide-based dispersant are preferable because they have a high effect of suppressing aggregation in the suspension of P3HA, and the alkylene oxide-based dispersant has a high processability of the obtained P3HA powder. More preferred.
- One of these types may be used alone, or two or more types may be used in combination.
- the alkylene oxide-based dispersant is not particularly limited as long as it exhibits the above effects, but is composed of a block of poly (ethylene oxide) (PEO) and a block of poly (propylene oxide) (PPO). It is preferably configured and in the form of PEO-PPO-PEO.
- poly (ethylene oxide) (PEO) block is intended to be a polymer portion formed by polymerizing ethylene oxide (EO) in the structure of an alkylene oxide-based dispersant.
- poly (propylene oxide) (PPO) block is intended to be a polymer portion formed by polymerizing propylene oxide (PO) in the structure of an alkylene oxide-based dispersant.
- the viscosity of the aqueous suspension is kept low and P3HA is produced with high productivity. be able to.
- the range of PEO molecular weight and PEO molecular weight / PPO molecular weight in the alkylene oxide-based dispersant is preferably the following combination.
- PEO molecular weight may be referred to as "EO molecular weight”
- PPO molecular weight may be referred to as "PO molecular weight”.
- the PEO molecular weight in the alkylene oxide-based dispersant may be 1500 or more, preferably 1750 or more, and more preferably 2000 or more.
- the upper limit of the PEO molecular weight in the alkylene oxide-based dispersant is, for example, 30,000 or less, preferably 25,000 or less, and more preferably 20,000 or less.
- the PEO molecular weight / PPO molecular weight in the alkylene oxide-based dispersant is preferably 0.5 or more, more preferably 0.6 or more, and 0.7 or more. Is even more preferable.
- the upper limit of the PEO molecular weight / PPO molecular weight is preferably 5.0 or less, more preferably 4.8 or less, and further preferably 4.5 or less.
- the alkylene oxide-based dispersant when the PEO molecular weight and the PEO molecular weight / PPO molecular weight in the alkylene oxide-based dispersant are within the above ranges, the alkylene oxide-based dispersant has hydrophilicity and the alkylene oxide-based dispersant is dispersed. Since the number of molecules increases with respect to the weight of the agent added, it is easy to maintain the dispersibility of the aqueous suspension.
- the alkylene oxide-based dispersant has a PEO molecular weight of 1500 or more and a PEO molecular weight / PPO molecular weight of 0.5 to 5.0.
- the alkylene oxide-based dispersant preferably has at least one PEO block having a molecular weight of 750 or more, and more preferably at least two or more.
- the upper limit thereof is not particularly limited, but is, for example, 4 or less, preferably 3 or less.
- the alkylene oxide-based dispersant has hydrophilicity.
- the PPO molecular weight in the alkylene oxide-based dispersant is not particularly limited, but is, for example, 500 or more, preferably 1500 or more. Further, in one embodiment of the present invention, the upper limit of the PPO molecular weight in the alkylene oxide-based dispersant is, for example, 6700 or less, preferably 6250 or less. When the PPO molecular weight in the alkylene oxide-based dispersant is within the above range, the alkylene oxide-based dispersant has hydrophobicity.
- the number of PPO blocks in the alkylene oxide-based dispersant is not particularly limited as long as the above effects are exhibited, and may be one or a plurality (for example, 2, 3, 4). ) May be.
- the alkylene oxide-based dispersant is, for example, a compound represented by the following formula (5).
- X is, for example, 17 to 340, preferably 20 to 285, and more preferably 22 to 226.
- X is 340 or less, the number of molecules increases with respect to the weight of the alkylene oxide-based dispersant added, so that the dispersibility of the aqueous suspension can be easily maintained, and when X is 17 or more, the aqueous suspension has hydrophilicity.
- Y is, for example, 8 to 115, preferably 10 to 110, and more preferably 24 to 107. When Y is 115 or less, it is easily dissolved in water, and when Y is 8 or more, it has hydrophobicity.
- Z is, for example, 17 to 340, preferably 20 to 285, and more preferably 22 to 226.
- the number of molecules increases with respect to the weight of the alkylene oxide-based dispersant added, so that the dispersibility of the aqueous suspension can be easily maintained, and when Z is 17 or more, the aqueous suspension has hydrophilicity.
- X + Z the sum of X and Z (hereinafter, may be referred to as “X + Z”) is, for example, 34 to 680, preferably 40 to 570, and more preferably. , 44-452.
- X + Z is 680 or less, the number of molecules increases with respect to the weight of the alkylene oxide-based dispersant added, so that the dispersibility of the aqueous suspension can be easily maintained, and when X is 34 or more, the aqueous suspension has hydrophilicity.
- a commercially available product may be used as the alkylene oxide-based dispersant.
- Commercially available products of alkylene oxide-based dispersants include, for example, Pluronic 10400 (manufactured by BASF), Pluronic 10500 (manufactured by BASF), Genapol PF80 (manufactured by Clariant), Unilube DP60-600B (manufactured by NOF Corporation), and Unilube DP60.
- the amount of the dispersant added to the P3HA aqueous suspension is not particularly limited, but is preferably 0.1 to 20 parts by mass with respect to 100 parts by mass of P3HA contained in the suspension, and is 0. .5 to 10 parts by mass is more preferable, and 0.75 to 5 parts by mass is further preferable.
- the addition amount of the dispersant within the above range, the dispersion stability of P3HA in the P3HA aqueous suspension is further improved, and the P3HA powder can be efficiently produced.
- the pH of the aqueous suspension of P3HA after the addition of the dispersant is adjusted to reduce the coloring when the P3HA is heated and melted, and to ensure the stability of the molecular weight during heating and / or drying. From the viewpoint, it is preferable to adjust to 7 or less, more preferably to 5 or less, and further preferably to 4 or less. Further, from the viewpoint of acid resistance of the container, it is preferable to prepare 1 or more, more preferably 2 or more, and further preferably 3 or more. By setting the pH of the P3HA aqueous suspension to 7 or less, the coloring when the P3HA powder is heated and melted (processed) is reduced, and the decrease in molecular weight during heating and / or drying can be suppressed.
- the pH adjusting method is not particularly limited, and examples thereof include a method of adding an acid.
- the acid is not particularly limited, and may be either an organic acid or an inorganic acid, and may or may not be volatile. More specifically, as the acid, for example, sulfuric acid, hydrochloric acid, phosphoric acid, acetic acid and the like can be used.
- the concentration of P3HA in the P3HA aqueous suspension obtained in the step (e) is economically advantageous in terms of drying utility and improves productivity, so that it is preferably 30% by weight or more, more preferably 40% by weight or more. It is preferable, and more preferably 50% by weight or more. Further, the upper limit of the concentration of P3HA is the closest packing, and sufficient fluidity may not be ensured. Therefore, 65% by weight or less is preferable, and 60% by weight or less is more preferable.
- the method for adjusting the concentration of P3HA is not particularly limited, and examples thereof include a method of adding an aqueous medium or removing a part of the aqueous medium (for example, by centrifuging and then removing the supernatant). .. The adjustment of the concentration of P3HA may be carried out at any stage of the step (e), or may be carried out at a stage before the step (e).
- the manufacturing method may further comprise step (f).
- Step (f) is a step of drying the P3HA aqueous suspension prepared in step (e).
- the drying method include a method of supplying a P3HA aqueous suspension in the form of fine droplets into a dryer and drying the suspension while in contact with hot air in the dryer (spray drying), vacuum drying and the like. .. Preferably, spray drying is used.
- the step (f) can also be said to be a drying step.
- the method (atomizer) of supplying the P3HA aqueous suspension in the form of fine droplets into the dryer is not particularly limited, and the method using a rotating disk and the method using a nozzle are not particularly limited. And the like, a known method can be mentioned.
- the contact method between the droplet and the hot air in the dryer is not particularly limited, and examples thereof include a parallel flow type, a countercurrent type, and a method in which these are used in combination.
- the drying temperature in the case of spray drying in the step (f) may be any temperature as long as it can remove most of the aqueous medium from the droplets of the P3HA aqueous suspension, and can be dried to the desired water content. It can be appropriately set under conditions that do not cause deterioration of quality (decrease in molecular weight, decrease in color tone, etc.), melting, etc. as much as possible.
- the temperature of the hot air blown into the spray dryer can be appropriately selected in the range of 100 to 300 ° C.
- the amount of hot air in the dryer can be appropriately set according to, for example, the size of the dryer.
- the step (f) may include a step of further drying the obtained P3HA (P3HA powder or the like) (for example, a step of subjecting to vacuum drying). ..
- the present production method may include other steps (for example, a step of adding various additives to a P3HA aqueous suspension).
- the P3HA powder according to the embodiment of the present invention has a weight average molecular weight of 100,000 to 600,000, a residual protein amount of 2000 ppm or less, and a particle surface. It is non-porous and has a weight average molecular weight retention rate of 50% or more represented by the following formula (1).
- Weight average molecular weight retention rate (%) (Weight average molecular weight of P3HA after heating at 160 ° C for 20 minutes / Weight average molecular weight of P3HA before heating at 160 ° C for 20 minutes) ⁇ 100 ...
- This P3HA powder is extremely useful in various fields because it does not generate foreign matter during processing, has excellent productivity, and has high thermal stability.
- the P3HA powder is produced by the above-mentioned production method.
- the present P3HA powder can be produced, for example, by a method for producing P3HA including the step (a), a method for producing P3HA including the steps (a) to (c), and the like. .. Regarding P3HA, except for the matters specified in this section, [2. The description in the [Method for producing P3HA] section is incorporated.
- the weight average molecular weight of the P3HA powder is 100,000 to 700,000, preferably 100,000 to 600,000, more preferably 100,000 to 500,000, still more preferably 100,000 to 400,000, and particularly preferably. Is 100,000 to 300,000, most preferably 100,000 to 250,000.
- the weight average molecular weight of the P3HA powder is 700,000 or less (particularly, 600,000 or less)
- the injection moldability and mechanical properties of the molded product can be improved by the effect of the nucleating agent when used during thermal processing.
- a P3HA powder having a low molecular weight is preferable because it has a more excellent nuclear agent effect.
- the weight average molecular weight of this P3HA powder is expressed as "final molecular weight" in the examples.
- the weight average molecular weight of the P3HA powder is measured by the method described in Examples ( ⁇ Final Molecular Weight>).
- the ratio (Mw / Mn) of the weight average molecular weight (final molecular weight) (Mw) to the number average molecular weight (Mn) of this P3HA powder is not particularly limited, but is 1.0 from the viewpoint of excellent molecular weight dispersibility. ⁇ 3.1 is preferable, 1.2 to 3.0 is more preferable, and 1.4 to 2.9 is even more preferable.
- the Mw / Mn of this P3HA powder is measured by the method described in Examples.
- the number average molecular weight (Mn) is a value used for evaluating the ratio (dispersity) to the weight average molecular weight (final molecular weight) (Mw), and is a value that increases or decreases substantially in proportion to Mw.
- the Mw / Mn of the P3HA powder is 1.0 to 3.1 means that there is little variation in the molecular weight, in other words, the molecular weight of the P3HA powder is monodisperse. According to this production method, P3HA powder having Mw / Mn of 1.0 to 3.1 can be obtained.
- the surface of the P3HA particles in the P3HA powder is non-porous.
- the dispersibility is good, so that the particles do not become agglomerated and the alkali used in the manufacturing process does not remain inside the agglomerates.
- the residual alkali does not serve as a hydrolysis catalyst during thermal processing, and the thermal stability is improved. Whether or not the surface of the P3HA particles is non-porous is measured by the method described in Examples.
- the P3HA powder has a weight average molecular weight retention rate represented by the formula (1) of 60% or more, preferably 63% or more, more preferably 65% or more, and particularly preferably 68% or more.
- the weight average molecular weight retention rate represented by the formula (1) is preferably as high as possible from the viewpoint of preventing deterioration of the P3HA powder during heating (during thermal processing), but if it is 50% or more, it is at least during heating (heat). It can prevent severe deterioration (during processing).
- the higher the weight average molecular weight retention rate represented by the formula (1), the better, and the upper limit is not particularly limited, but for example, it is 90%, preferably 95%, more preferably 98% or less, and 100%. Most preferred.
- the weight average molecular weight retention rate represented by the formula (1) is measured by the method described in Examples. When the particle surface of P3HA is porous, the weight average molecular weight retention rate represented by the above formula (1) tends to be low.
- the amount of residual protein in the P3HA powder is 2000 ppm or less, preferably 1900 ppm or less, and more preferably 1800 ppm or less.
- the amount of residual protein in the P3HA powder can serve as an indicator of the amount of various components in the P3HA powder that are produced or not removed during the manufacturing process.
- the amount of residual protein of the P3HA is 2000 ppm or less, impurities are unlikely to affect the physical properties of the P3HA powder, and foreign matter is not generated during processing, so that a quality-stable P3HA powder can be provided.
- the smaller the amount of residual protein in the P3HA, the better, and the lower limit thereof is not particularly limited, but for example, it may be 200 ppm or more, preferably 100 ppm or more, more preferably 50 ppm or more, or 0 ppm.
- the amount of residual protein in this P3HA powder is measured by the method described in Examples.
- the bulk density of the P3HA powder is not particularly limited, but is preferably 0.20 g / mL or more, more preferably 0.25 g / mL or more, and 0.30 g / mL from the viewpoint of achieving excellent fluidity. The above is more preferable.
- the upper limit of the bulk density of the P3HA powder is not particularly limited, but may be, for example, 0.50 mg / mL or less.
- the bulk density of this P3HA powder is measured by the following method.
- the measurement is performed using a device in which a damper (for example, a metal plate) is attached to the device.
- a damper for example, a metal plate
- the median particle size (average particle size) of the P3HA powder is not particularly limited, but is preferably 60 to 1000 ⁇ m, more preferably 100 to 500 ⁇ m from the viewpoint of dust explosion prevention and powder fluidity.
- the median particle size of the P3HA powder is measured using a laser diffraction / scattering type particle size distribution measuring device LA-950 (HORIBA). Specifically, 0.05 g of sodium dodecyl sulfate, which is a surfactant, is added to 20 ml of ion-exchanged water as a dispersant to obtain an aqueous surfactant solution. Next, 0.2 g of P3HA powder is added to the aqueous surfactant solution and dispersed to obtain a P3HA dispersion liquid. Then, the P3HA dispersion liquid is introduced into the laser diffraction / scattering type particle size distribution measuring device LA-950 manufactured by HORIBA, and the median particle size of the P3HA powder is measured.
- one embodiment of the present invention is as follows.
- ⁇ 1> A method for producing a poly (3-hydroxy alkanoate) having a weight average molecular weight of 100,000 to 700,000.
- An enzyme is added to the culture broth obtained in the step (a) to enzymatically treat the cells, and
- an alkaline aqueous solution is added to the culture broth obtained in the step (b). Then, the step of adjusting the pH to 10.0 to 12.0,
- a method for producing a poly (3-hydroxy alkanoate) which comprises.
- ⁇ 2> The poly (3-hydroxyalkano) according to ⁇ 1>, wherein the enzyme treatment in the step (b) includes performing an alkaline proteolytic enzyme treatment, a bacteriolytic enzyme treatment, and an alkaline proteolytic enzyme treatment in this order.
- manufacturing method ⁇ 3> Between the steps (a) and (b), (a') a step of adjusting the pH of the culture solution obtained in the step (a) to 6.0 to 8.0.
- the enzyme treatment in the step (b) comprises performing a lytic enzyme treatment and an alkaline proteolytic enzyme treatment in this order.
- ⁇ 4> The method for producing a poly (3-hydroxyalkanoate) according to any one of ⁇ 1> to ⁇ 3>, wherein the enzyme in the step (b) is lysozyme and alcalase.
- ⁇ 5> After the step (c), (c') a step of adding a surfactant to the culture solution obtained in the step (c).
- the method for producing a poly (3-hydroxyalkanoate) according to any one of ⁇ 1> to ⁇ 4> which comprises.
- ⁇ 6> The method for producing a poly (3-hydroxyalkanoate) according to any one of ⁇ 1> to ⁇ 5>, wherein the reaction time in the step (a) is 4 hours to 30 hours.
- ⁇ 7> The poly (3) according to any one of ⁇ 1> to ⁇ 6>, wherein the poly (3-hydroxy alkanoate) is a poly (3-hydroxybutyrate-co-3-hydroxyhexanoate). 3-Hydroxy alkanoate) manufacturing method.
- the weight average molecular weight is 100,000 to 600,000, the residual protein amount is 2000 ppm or less, the particle surface is non-porous, and the weight average molecular weight retention rate represented by the following formula (1) is Poly (3-hydroxy alkanoate) powder which is 50% or more.
- Weight average molecular weight retention rate (%) (Weight average molecular weight of P3HA after heating at 160 ° C for 20 minutes / Weight average molecular weight of P3HA before heating at 160 ° C for 20 minutes) ⁇ 100 ... (1) ⁇ 9> The poly (3-hydroxyalkanoate) according to ⁇ 8>, wherein the ratio (Mw / Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) is 1.0 to 3.1. powder.
- P3HB3HH is used as “P3HA”
- P3HA can be read as “P3HB3HH”.
- Thermal stability was evaluated as the weight average molecular weight retention of P3HA after heating at 160 ° C. for 20 minutes.
- the weight average molecular weight of this solution was measured using a GPC system manufactured by Shimadzu Corporation equipped with "Shodex K805L (300 x 8 mm, two concatenated)" (manufactured by Showa Denko KK) using chloroform as a mobile phase.
- a Shodex K-804 (polystyrene gel) manufactured by Showa Denko KK was used as the molecular weight standard sample.
- the P3HA powder was preheated at 160 ° C. for 7 minutes and then heated at 160 ° C. for 20 minutes under 5 MPa pressurization to prepare a P3HA resin sheet.
- the weight average molecular weight of P3HA after heating was measured by the same procedure as described in (Measurement of weight average molecular weight of P3HA before heating) except that 10 mg of the P3HA resin sheet was dissolved in 10 mL of chloroform. did.
- the initial molecular weight was measured by the following procedure: the inactivated culture containing P3HA was diluted with distilled water, centrifuged and then the supernatant was removed. Ethanol was added to the obtained precipitate (P3HA), dispersed in ethanol, and centrifuged. The supernatant was removed and dried in a vacuum dryer for 1 hour or more, and the precipitate was completely dried to obtain a dried product (P3HA powder). 10 mg of the obtained P3HA powder was dissolved in 10 mL of chloroform, and then the insoluble material was removed by filtration.
- the yield of P3HA was measured by the following procedure: (A) 2 g each of the culture solution before the molecular weight adjustment and the culture solution after the molecular weight adjustment, which will be described later, were taken, and the solid content concentration was measured using a moisture meter (ML-50 manufactured by A & D Co., Ltd.).
- ⁇ Amount of remaining protein> The amount of residual protein was measured using a BCA Protein Assay Kit (manufactured by Thermo Fisher Scientific).
- ⁇ SEM> A carbon tape was attached on the SEM sample table, and P3HA powder containing an external additive or P3HA powder as a comparative example was sprinkled on the carbon tape, and then the excess powder was removed with a blower.
- the pretreatment was performed by coating with a thickness of 20 nm using an osmium plasma coater.
- the pretreatment of the P3HA powder was carried out using an OPC60A-G osmium plasma coater manufactured by Filgen. SEM observation was performed using S-4800 manufactured by Hitachi High-Tech Fielding.
- Example 1 (Preparation of cell culture solution) Ralstonia eutropha described in International Publication No. WO2019 / 142717 was cultured by the method described in paragraphs [0041] to [0048] of the same document to obtain a cell culture solution containing cells containing P3HA.
- composition ratio of the repeating unit of P3HA composition ratio of 3-hydroxybutyrate unit / 3-hydroxyhexanoate unit
- Alkalase manufactured by Novozymes
- 30% sodium hydroxide was added at 50 ° C., and the pH was adjusted to 8.5 and maintained for 2 hours.
- This P3HA aqueous suspension was dried at 60 ° C. for 12 hours or more to obtain P3HA powder.
- the final molecular weight (Mw) of the obtained P3HA powder was 173000, the number average molecular weight (Mn) was 70,000, and the thermal stability was 73% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Corporation), it was confirmed that the surface was non-porous (FIG. 1).
- Example 2 Until (molecular weight adjustment), a liquid after molecular weight adjustment was obtained by the same method as in Example 1.
- Enzyme treatment IW (industrial water) was added to the liquid after adjusting the molecular weight (the liquid after adjusting the molecular weight) obtained above to adjust the solid content concentration to 18%. Then, 2.5 L of Alcalase (manufactured by Novozymes), which is an alkaline proteolytic enzyme, was added and kept at 50 ° C. for 2 hours. Next, lysozyme (manufactured by Wako Pure Chemical Industries, Ltd.), which is a lytic enzyme that decomposes sugar chains (peptidoglycan) in the cell wall, was added and kept at 50 ° C. for 2 hours.
- Alcalase manufactured by Novozymes
- lysozyme manufactured by Wako Pure Chemical Industries, Ltd.
- the yield of P3HA was 97%, and the amount of residual protein was 760 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 173000, the number average molecular weight (Mn) was 70,000, and the thermal stability was 70% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Example 3 The composition ratio of the repeating unit of P3HA (composition ratio of 3-hydroxybutyrate unit / 3-hydroxyhexanoate unit) is 96.0 / 4.0 to 92.0 / 8.0 (mol / mol).
- a P3HA powder was obtained in the same manner as in Example 1 except that the above was used. In addition, various measurements were performed in the same manner as in Example 1.
- the yield of P3HA was 98%, and the amount of residual protein was 1647 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 158,000, the number average molecular weight (Mn) was 84,000, and the thermal stability was 78% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Example 4 The composition ratio of the repeating unit of P3HA (composition ratio of 3-hydroxybutyrate unit / 3-hydroxyhexanoate unit) is 92.0 / 8.0 to 87.0 / 13.0 (mol / mol).
- a P3HA powder was obtained in the same manner as in Example 1 except that the above was used. In addition, various measurements were performed in the same manner as in Example 1.
- the yield of P3HA was 99%, and the amount of residual protein was 1704 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 257,000, the number average molecular weight (Mn) was 91,000, and the thermal stability was 80% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Example 5 Until (inactivation), an inactivated culture solution was obtained in the same manner as in Example 3.
- Lysozyme (Fujifilm) is an enzyme that decomposes sugar chains (peptidoglycan) in the cell wall after adjusting the solid content concentration to 18% by adding IW (industrial water) to the inactivated culture solution obtained above. Wako Pure Chemical Industries, Ltd.) was added, and the mixture was kept at 50 ° C. for 2 hours. Then, 2.5 L of alcalase (manufactured by Novozymes), which is a proteolytic enzyme, was added, and then 30% sodium hydroxide was added at 50 ° C., and the pH was adjusted to 8.5 and maintained for 2 hours.
- IW industrial water
- the yield of P3HA was 30%, and the amount of residual protein was 796 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 224000, the number average molecular weight (Mn) was 61000, and the thermal stability was 3% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was porous.
- Example 6 The composition ratio of the repeating unit of P3HA (composition ratio of 3-hydroxybutyrate unit / 3-hydroxyhexanoate unit) is 92.0 / 8.0 to 87.0 / 13.0 (mol / mol).
- a P3HA powder was obtained in the same manner as in Example 5 except that the above was used. In addition, various measurements were performed in the same manner as in Example 5.
- the yield of P3HA was 96%, and the amount of residual protein was 1326 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 556,000, the number average molecular weight (Mn) was 287,000, and the thermal stability was 80% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Example 1 (Lysis, concentration) Sodium dodecyl sulfate (SDS, manufactured by Kao Corporation) was added so as to be 0.6 to 1.0 wt% with respect to the enzyme treatment solution obtained above, and the mixture was diluted 2-fold. Then, the pH was adjusted to 8.5 with 30% sodium hydroxide. After that, P3HA particles were obtained by the same method as in Example 1. In addition, various measurements were performed in the same manner as in Example 1.
- the yield of P3HA was 97%, and the amount of residual protein was 3547 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 216000, the number average molecular weight (Mn) was 86000, and the thermal stability was 63% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Lysozyme (Fujifilm) is an enzyme that decomposes sugar chains (peptidoglycan) in the cell wall after adjusting the solid content concentration to 18% by adding IW (industrial water) to the inactivated culture solution obtained above. Wako Pure Chemical Industries, Ltd.) was added, and the mixture was kept at 50 ° C. for 2 hours. Then, 2.5 L of alcalase (manufactured by Novozymes), which is a proteolytic enzyme, was added, and then 30% sodium hydroxide was added at 50 ° C., and the pH was adjusted to 8.5 and maintained for 2 hours.
- IW industrial water
- the yield of P3HA was 30%, and the amount of residual protein was 796 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 224000, the number average molecular weight (Mn) was 61000, and the thermal stability was 3% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was porous.
- composition ratio of the repeating unit of P3HA is 96.0 / 4.0 to 92.0 / 8.0 (mol / mol).
- a P3HA powder was obtained in the same manner as in Comparative Example 2 except that the above was used. In addition, various measurements were performed in the same manner as in Example 1.
- the yield of P3HA was 85%, and the amount of residual protein was 1263 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 287,000, the number average molecular weight (Mn) was 68,000, and the thermal stability was 71% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was porous.
- composition ratio of the repeating unit of P3HA is 92.0 / 8.0 to 87.0 / 13.0 (mol / mol).
- a P3HA powder was obtained in the same manner as in Comparative Example 2 except that the above was used. In addition, various measurements were performed in the same manner as in Example 1.
- the yield of P3HA was 80%, and the amount of residual protein was 1806 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 250,000, the number average molecular weight (Mn) was 78,000, and the thermal stability was 57% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was porous.
- the yield of P3HA was 94%, and the amount of residual protein was 1214 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 652000, the number average molecular weight (Mn) was 336000, and the thermal stability was 78% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- the yield of P3HA was 88%, and the amount of residual protein was 1050 ppm (Table 1).
- the final molecular weight (Mw) of the obtained P3HA powder was 603000, the number average molecular weight (Mn) was 322000, and the thermal stability was 80% (Table 1). Furthermore, when the state of the P3HA powder surface was observed using an electron microscope (SEM, S-4800 manufactured by Hitachi High-Tech Co., Ltd.), it was confirmed that the surface was non-porous.
- Table 1 shows the physical properties measured in Examples 1 to 6 and Comparative Examples 1 to 6, and FIG. 3 shows the operations performed in Examples 1 to 6 and Comparative Examples 1 to 6 and their order.
- P3HA with reduced impurities can be produced in high yield.
- P3HA with reduced impurities (particularly residual protein) obtained by the production method of the present invention can be used in agriculture, fisheries, forestry, horticulture, medicine, hygiene, clothing, non-clothing, packaging, automobiles, building materials, and others. It can be suitably used in the field.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
重量平均分子量保持率(%)=(160℃で20分間加熱した後のP3HAの重量平均分子量/160℃で20分間加熱する前のP3HAの重量平均分子量)×100 ・・・(1)
本発明の一実施形態に係るポリ(3-ヒドロキシアルカノエート)の製造方法(以下、「本製造方法」と称する。)は、重量平均分子量が10万~70万であるポリ(3-ヒドロキシアルカノエート)の製造方法であり、(a)ポリ(3-ヒドロキシアルカノエート)を含有する菌体を含む培養液にアルカリ水溶液を添加して、pHを8.0~12.0に調整する工程、(b)前記工程(a)で得られた培養液に酵素を添加して、前記菌体を酵素処理する工程、および(c)前記工程(b)で得られた培養液にアルカリ水溶液を添加して、pHを10.0~12.0に調整する工程、を含むことを特徴とする。
・熱安定性に優れていること。
・分子量分布の観点から、同程度の分子量のP3HAを多く含むこと(単分散)。
・低分子量のP3HAを製造した場合、得られたP3HA粉体の表面が非多孔質となること。
本製造方法は、以下の工程(a)~(c)を含む、重量平均分子量が10万~70万であるポリ(3-ヒドロキシアルカノエート)のP3HAの製造方法である。
工程(a)は、P3HAを含有する菌体を含む培養液にアルカリ水溶液を添加して(「アルカリ処理」ともいう。)、pHを8.0~12.0に調整する工程である。すなわち、pHを8.0~12.0に調整することで、P3HAを加水分解し、P3HAの分子量を調整する工程であるともいえる。当該工程によれば、P3HAを含有する菌体において、菌体中で(換言すると、当該P3HAが結晶化していない(アモルファスな)状態で)、当該P3HAの分子量を調整することができる。工程(a)は、P3HAを含有する菌体を含む培養液を、pHが8.0~12.0の状態に一定時間維持する工程であるとも言える。また、工程(a)は、分子量調整工程であるとも言える。
本明細書において、「P3HA」とは、以下の式(2):
[-O-CHR-CH2-CO-] (2)
(式中、Rは、CnH2n+1で表されるアルキル基であり、nは、1~15の整数である。)で示される1種以上の単位からなる共重合体の総称を意図する。
本明細書において、「P3HAを含有する菌体」とは、P3HAを生産する微生物を意図する。すなわち、本発明の一実施形態において、P3HAは、微生物により産生される。本製造方法において用いられる微生物は、細胞内にP3HAを生成し得る微生物である限り、特に限定されない。例えば、天然から単離された微生物や菌株の寄託機関(例えば、IFO、ATCC等)に寄託されている微生物、またはそれらから調製し得る変異体や形質転換体等を使用できる。より詳しくは、例えば、カプリアビダス(Cupriavidus)属、アルカリゲネス(Alcaligenes)属、ラルストニア(Ralstonia)属、シュウドモナス(Pseudomonas)属、バチルス(Bacillus)属、アゾトバクター(Azotobacter)属、ノカルディア(Nocardia)属、アエロモナス(Aeromonas)属の菌等が挙げられる。中でも、アエロモナス属、アルカリゲネス属、ラルストニア属、またはカプリアビダス属に属する微生物が好ましい。特に、アルカリゲネス・リポリティカ(A.lipolytica)、アルカリゲネス・ラトゥス(A.latus)、アエロモナス・キャビエ(A.caviae)、アエロモナス・ハイドロフィラ(A.hydrophila)、カプリアビダス・ネカトール(C.necator)等の菌株がより好ましく、カプリアビダス・ネカトールが最も好ましい。
本発明の一実施形態において、アルカリ水溶液は、塩基性化合物を含む水溶液である。アルカリ水溶液に含まれる塩基性化合物としては、特に限定されないが、例えば、水酸化ナトリウム、水酸化カリウム等のアルカリ金属またはアルカリ土類金属の水酸化物;炭酸ナトリウム、炭酸カリウム等の金属炭酸塩;リン酸ナトリウム、リン酸カリウム、リン酸水素ナトリウム、リン酸水素カリウム等の金属リン酸塩または金属リン酸水素塩等が挙げられる。
P3HA含量(g/g)=(乾燥物の重量(g)/培養液の重量(g))・・・(3)
P3HAの収率(%)=(分子量調整後の培養液のP3HA含量/分子量調整前の培養液のP3HA含量)×100×(分子量調整前の培養液の固形分濃度(%)/分子量調整後の培養液の固形分濃度(%)) ・・・(4)
上記式(3)および(4)中の各種パラメータは、実施例に記載の方法により測定される。
工程(b)は、前記工程(a)で得られた培養液に酵素を添加して、前記菌体を酵素処理する工程である。当該工程によれば、前記菌体由来の不純物(細胞壁、タンパク質等)を破壊および除去することで、前記菌体からP3HAを効率的に回収できる。
本明細書において、「アルカリ性タンパク質分解酵素」とは、アルカリ環境下(例えばpH8.5の溶液中)でタンパク質を分解する活性を有するタンパク質分解酵素を意図する。
本発明の一実施形態において、アルカリ性タンパク質分解酵素処理とは、溶菌酵素を前記培養液に添加し、前記菌体を酵素処理する工程である。
本製造方法は、工程(a)と(b)との間に、さらに工程(a’)を含み得る。
工程(c)は、前記工程(b)で得られた培養液にアルカリ水溶液を添加して、pHを10.0~12.0に調整する工程である。当該工程によれば、P3HAの分子量をさらに小さく調整し得るとともに、菌体を破砕する際に、菌体由来の不純物(核酸、タンパク質等)を分散および溶解することで、高純度のP3HAを菌体から分離することができる。工程(c)は、アルカリ洗浄工程とも言える。
本製造方法は、工程(c)の後に、さらに工程(c’)を含み得る。工程(c’)は界面活性剤処理工程であるとも言える。
本発明の一実施形態において、本製造方法は、工程(d)をさらに含み得る。
本発明の一実施形態において、本製造方法は、工程(e)をさらに含み得る。
・工程(e1):P3HA水性懸濁液に分散剤を添加する工程
・工程(e2):P3HA水性懸濁液のpHを7以下に調整する工程
工程(e1)と工程(e2)とを実施する順番は、特に限定されないが、工程(e2)におけるP3HAの凝集が抑制され、よりP3HAの分散安定性に優れた水性懸濁液が得られる観点で、工程(e1)の後に工程(e2)を実施することが好ましい。
本発明の一実施形態において、本製造方法は、工程(f)をさらに含み得る。
本発明の一実施形態に係るP3HA粉体(以下、「本P3HA粉体」と称する。)は、重量平均分子量が10万~60万であり、残タンパク質量が2000ppm以下であり、粒子表面が非多孔質であり、かつ、以下の式(1)で示される重量平均分子量保持率が50%以上である。
重量平均分子量保持率(%)=(160℃で20分間加熱した後のP3HAの重量平均分子量/160℃で20分間加熱する前のP3HAの重量平均分子量)×100 ・・・(1)
本P3HA粉体は、加工時に異物が発生せず、生産性に優れ、かつ、高い熱安定性を有するため、種々の分野において極めて有用である。
<1>重量平均分子量が10万~70万であるポリ(3-ヒドロキシアルカノエート)の製造方法であり、
(a)ポリ(3-ヒドロキシアルカノエート)を含有する菌体を含む培養液にアルカリ水溶液を添加して、pHを8.0~12.0に調整する工程、
(b)前記工程(a)で得られた培養液に酵素を添加して、前記菌体を酵素処理する工程、および
(c)前記工程(b)で得られた培養液にアルカリ水溶液を添加して、pHを10.0~12.0に調整する工程、
を含む、ポリ(3-ヒドロキシアルカノエート)の製造方法。
<2>前記工程(b)における酵素処理が、アルカリ性タンパク質分解酵素処理、溶菌酵素処理、およびアルカリ性タンパク質分解酵素処理をこの順で行うことを含む、<1>に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
<3>前記工程(a)と(b)との間に、さらに
(a’)前記工程(a)で得られた培養液のpHを6.0~8.0に調整する工程、
を含み、
前記工程(b)における酵素処理が、溶菌酵素処理、およびアルカリ性タンパク質分解酵素処理をこの順で行うことを含む、<1>または<2>に記載の製造方法。
<4>前記工程(b)における酵素が、リゾチームおよびアルカラーゼである、<1>~<3>のいずれかに記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
<5>前記工程(c)の後に、さらに
(c’)前記工程(c)で得られた培養液に界面活性剤を添加する工程、
を含む、<1>~<4>のいずれかに記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
<6>前記工程(a)の反応時間が4時間~30時間である、<1>~<5>のいずれかに記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
<7>前記ポリ(3-ヒドロキシアルカノエート)が、ポリ(3-ヒドロキシブチレート-コ-3-ヒドロキシヘキサノエート)である、<1>~<6>のいずれか1に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
<8>重量平均分子量が10万~60万であり、残タンパク質量が2000ppm以下であり、粒子表面が非多孔質であり、かつ、以下の式(1)で示される重量平均分子量保持率が50%以上である、ポリ(3-ヒドロキシアルカノエート)粉体。
重量平均分子量保持率(%)=(160℃で20分間加熱した後のP3HAの重量平均分子量/160℃で20分間加熱する前のP3HAの重量平均分子量)×100 ・・・(1)
<9>重量平均分子量(Mw)と数平均分子量(Mn)との比(Mw/Mn)が、1.0~3.1である、<8>に記載のポリ(3-ヒドロキシアルカノエート)粉体。
実施例および比較例における測定および評価を、以下の方法で行った。
熱安定性は、160℃で20分間加熱した後のP3HAの重量平均分子量保持率として評価した。P3HAの重量平均分子量保持率は、以下の式(1)によって算出した:
重量平均分子量保持率(%)=(加熱した後のP3HAの重量平均分子量/加熱する前のP3HAの重量平均分子量)×100 ・・・(1)
(加熱する前のP3HAの重量平均分子量)
P3HA粉体10mgを、クロロホルム10mLに溶解させた後、不溶物を濾過により除いた。この溶液(濾液)を、「Shodex K805L(300x8mm、2本連結)」(昭和電工社製)を装着した島津製作所製GPCシステムを用い、クロロホルムを移動相として重量平均分子量を測定した。分子量標準サンプルには、昭和電工(株)製Shodex K-804(ポリスチレンゲル)を用いた。
P3HA粉体を、160℃で7分間予熱処理した後、5MPa加圧下、160℃で20分間加熱し、P3HA樹脂シートを作製した。当該P3HA樹脂シート10mgをクロロホルム10mLに溶解させたこと以外は、(加熱する前のP3HAの重量平均分子量の測定)に記載したのと同様の手順で、加熱した後のP3HAの重量平均分子量を測定した。
初期分子量を以下の手順によって測定した:不活化後のP3HAを含む培養液を蒸留水で希釈し、遠心分離を行った後、上清を除去した。得られた沈殿物(P3HA)にエタノールを加え、エタノールに分散させ、遠心分離を行った。上清を除去し、真空乾燥器で1時間以上乾燥させ、沈殿物を完全に乾燥させ、乾燥体(P3HA粉体)を得た。得られたP3HA粉体10mgを、クロロホルム10mLに溶解させた後、不溶物を濾過により除いた。この溶液(濾液)を、「Shodex K805L(300x8mm、2本連結)」(昭和電工社製)を装着した島津製作所製GPCシステムを用い、クロロホルムを移動相として初期分子量を測定した。分子量標準サンプルには、昭和電工(株)製Shodex K-804(ポリスチレンゲル)を用いた。
最終分子量および数平均分子量を以下の手順によって測定した:P3HA粉体10mgを、クロロホルム10mLに溶解させた後、不溶物を濾過により除いた。この溶液(濾液)を、「Shodex K805L(300x8mm、2本連結)」(昭和電工社製)を装着した島津製作所製GPCシステムを用い、クロロホルムを移動相として最終分子量および数平均分子量を測定した。分子量標準サンプルには、昭和電工(株)製Shodex K-804(ポリスチレンゲル)を用いた。
P3HAの収率を以下の手順によって測定した:
(a)後述する分子量調整前の培養液と分子量調整後の培養液とをそれぞれ2gずつ採り、水分計(株式会社エー・アンド・デイ製ML-50)を用いて固形分濃度を測定した。
収率(%)=(分子量調整後の培養液のP3HA含量/分子量調整前の培養液のP3HA含量)×100×(分子量調整前の培養液の固形分濃度(%)/分子量調整後の培養液の固形分濃度(%)) ・・・(4)。
残タンパク質量は、BCA Protein Assay Kit(Thermo Fisher Scientific社製)を用いて測定した。
SEM試料台の上にカーボンテープを貼り、その上から外添剤を含有したP3HA粉体、または比較例となるP3HA粉体を振りかけ後、過剰な粉体をブロアーで除去した。前処理は、オスミウム・プラズマコーターを用いて、20nmの厚みでコーティングを行った。上記P3HA粉体の前処理は、フィルジェン製 OPC60A-Gオスミウム・プラズマコーターを用いて行った。SEM観察は、日立ハイテクフィールディング製 S-4800を用いて行った。
(菌体培養液の調製)
国際公開第WO2019/142717号に記載のラルストニア・ユートロファを、同文献の段落〔0041〕~〔0048〕に記載の方法で培養し、P3HAを含有する菌体を含む菌体培養液を得た。P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)を測定したところ、99.9/0.1~96.0/4.0(mol/mol)であった。
上記で得られた菌体培養液を内温70℃で8時間加熱・攪拌処理し、滅菌処理を行った。
上記で得られた不活化した培養液(不活化培養液)に対して30%水酸化ナトリウムを用いてpHを9.0±0.2に調整し、内温を75±2℃として、菌体中のP3HAの分子量調整を12時間行った。P3HAの収率は、97%であった(表1)。
上記で得られた分子量調整後の液(分子量調整後液)に対して95%硫酸を添加してpHを7.0±0.2に調整した。IW(工業用水)を添加して固形分濃度を18%に調整した後、細胞壁中の糖鎖(ペプチドグリカン)を分解する酵素(溶菌酵素)であるリゾチーム(富士フイルム和光純薬(株)社製)を添加し、50℃で2時間保持した。その後、アルカリ性タンパク質分解酵素であるアルカラーゼ2.5L(Novozyme社製)を添加し、次いで、50℃で30%水酸化ナトリウムを添加して、pH8.5に調整しながら2時間保持した。
上記で得られた酵素処理液に対して30%水酸化ナトリウムを添加してpH8.5に調整した(アルカリ洗浄)。次いで、上記酵素処理液に対して0.6~1.0wt%になるようにドデシル硫酸ナトリウム(SDS、花王製)を添加した(界面活性剤処理)。その後、pHが11.0±0.2になるように30%水酸化ナトリウムを用いて調整するとともに、pH11.0の水酸化ナトリウム水溶液を添加して、上記酵素処理液に対して2倍になるよう希釈した。
上記で得られたP3HA水性懸濁液に、エチレンオキサイド/プロピレンオキサイド共重合体非イオン性分散剤(ポリエチレンオキサイド分子量8000、ポリプロピレンオキサイド分子量2000、商品名プロノン208)を1.0phr(水性懸濁液中に存在するP3HA100重量部に対して1重量部)添加し、混合した。この液を120分間撹拌した後、P3HA水性懸濁液100gあたりに対して、10重量%硫酸を0.3ml添加し、P3HA水性懸濁液を得た。
(分子量調整)までは、実施例1と同様の方法で分子量調整後液を得た。
上記で得られた分子量調整後の液(分子量調整後液)に対してIW(工業用水)を添加して固形分濃度を18%に調整した。次いで、アルカリ性タンパク質分解酵素であるアルカラーゼ2.5L(Novozyme社製)を添加し、50℃で2時間保持した。次いで、細胞壁中の糖鎖(ペプチドグリカン)を分解する溶菌酵素であるリゾチーム(富士フイルム和光純薬(株)社製)を添加し、50℃で2時間保持した。その後、アルカラーゼ2.5L(Novozyme社製)を添加し、次いで、50℃で30%水酸化ナトリウムを添加して、pH8.5に調整しながら2時間保持した。以降は、実施例1と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。
P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)が96.0/4.0~92.0/8.0(mol/mol)であるP3HAを用いたこと以外は、実施例1と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。
P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)が92.0/8.0~87.0/13.0(mol/mol)であるP3HAを用いたこと以外は、実施例1と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。
(不活化)までは、実施例3と同様の方法で不活化培養液を得た。
上記で得られた不活化培養液に対してIW(工業用水)を添加して固形分濃度を18%に調整した後、細胞壁中の糖鎖(ペプチドグリカン)を分解する酵素であるリゾチーム(富士フイルム和光純薬(株)社製)を添加し、50℃で2時間保持した。その後、タンパク質分解酵素であるアルカラーゼ2.5L(Novozyme社製)を添加し、次いで、50℃で30%水酸化ナトリウムを添加して、pH8.5に調整しながら2時間保持した。
上記で得られた酵素処理後液に対して30%水酸化ナトリウムを用いてpHを11.5±0.2に調整し、内温を50±2℃として、P3HAの分子量調整を12時間行った。以降は、実施例1と同様の方法でP3HA粒子を得た。また、実施例1と同様の方法で、各種測定を行った。なお、P3HAの収率は、(溶菌、濃縮)の直前(換言すれば、pHを11.5±0.2に調整し、内温を50±2℃として12時間保持した直後)に計測した。
P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)が92.0/8.0~87.0/13.0(mol/mol)であるP3HAを用いたこと以外は、実施例5と同様の方法でP3HA粉体を得た。また、実施例5と同様の方法で、各種測定を行った。
(酵素処理)までは、実施例1と同様の方法で酵素処理液を得た。
上記で得られた酵素処理液に対して0.6~1.0wt%になるようにドデシル硫酸ナトリウム(SDS、花王製)を添加し、2倍希釈した。次いで、pHが8.5になるように30%水酸化ナトリウムを用いて調整した。以降は、実施例1と同様の方法でP3HA粒子を得た。また、実施例1と同様の方法で、各種測定を行った。
(不活化)までは、実施例1と同様の方法で不活化培養液を得た。
上記で得られた不活化培養液に対してIW(工業用水)を添加して固形分濃度を18%に調整した後、細胞壁中の糖鎖(ペプチドグリカン)を分解する酵素であるリゾチーム(富士フイルム和光純薬(株)社製)を添加し、50℃で2時間保持した。その後、タンパク質分解酵素であるアルカラーゼ2.5L(Novozyme社製)を添加し、次いで、50℃で30%水酸化ナトリウムを添加して、pH8.5に調整しながら2時間保持した。
上記で得られた酵素処理後液に対して30%水酸化ナトリウムを用いてpHを11.5±0.2に調整し、内温を50±2℃として、P3HAの分子量調整を12時間行った。以降は、実施例1と同様の方法でP3HA粒子を得た。また、実施例1と同様の方法で、各種測定を行った。なお、P3HAの収率は、(溶菌、濃縮)の直前(換言すれば、pHを11.5±0.2に調整し、内温を50±2℃として12時間保持した直後)に計測した。
P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)が96.0/4.0~92.0/8.0(mol/mol)であるP3HAを用いたこと以外は、比較例2と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。
P3HAの繰り返し単位の組成比(3-ヒドロキシブチレート単位/3-ヒドロキシヘキサノエート単位の組成比)が92.0/8.0~87.0/13.0(mol/mol)であるP3HAを用いたこと以外は、比較例2と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。
(分子量調整)で分子量調整を6時間行ったこと以外は、比較例3と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。なお、P3HAの収率は、(溶菌、濃縮)の直前(換言すれば、pHを11.5±0.2に調整し、内温を50±2℃として6時間保持した直後)に計測した。
(分子量調整)で分子量調整を6時間行ったこと以外は、比較例4と同様の方法でP3HA粉体を得た。また、実施例1と同様の方法で、各種測定を行った。なお、P3HAの収率は、(溶菌、濃縮)の直前(換言すれば、pHを11.5±0.2に調整し、内温を50±2℃として6時間保持した直後)に計測した。
Claims (9)
- 重量平均分子量が10万~70万であるポリ(3-ヒドロキシアルカノエート)の製造方法であり、
(a)ポリ(3-ヒドロキシアルカノエート)を含有する菌体を含む培養液にアルカリ水溶液を添加して、pHを8.0~12.0に調整する工程、
(b)前記工程(a)で得られた培養液に酵素を添加して、前記菌体を酵素処理する工程、および
(c)前記工程(b)で得られた培養液にアルカリ水溶液を添加して、pHを10.0~12.0に調整する工程、
を含む、ポリ(3-ヒドロキシアルカノエート)の製造方法。 - 前記工程(b)における酵素処理が、アルカリ性タンパク質分解酵素処理、溶菌酵素処理、およびアルカリ性タンパク質分解酵素処理をこの順で行うことを含む、請求項1に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
- 前記工程(a)と(b)との間に、さらに
(a’)前記工程(a)で得られた培養液のpHを6.0~8.0に調整する工程、
を含み、
前記工程(b)における酵素処理が、溶菌酵素処理、およびアルカリ性タンパク質分解酵素処理をこの順で行うことを含む、請求項1または2に記載の製造方法。 - 前記工程(b)における酵素が、リゾチームおよびアルカラーゼである、請求項1~3のいずれか1項に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
- 前記工程(c)の後に、さらに
(c’)前記工程(c)で得られた培養液に界面活性剤を添加する工程、
を含む、請求項1~4のいずれか1項に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。 - 前記工程(a)の反応時間が4時間~30時間である、請求項1~5のいずれか1項に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
- 前記ポリ(3-ヒドロキシアルカノエート)が、ポリ(3-ヒドロキシブチレート-コ-3-ヒドロキシヘキサノエート)である、請求項1~6のいずれか1項に記載のポリ(3-ヒドロキシアルカノエート)の製造方法。
- 重量平均分子量が10万~60万であり、残タンパク質量が2000ppm以下であり、粒子表面が非多孔質であり、かつ、以下の式(1)で示される重量平均分子量保持率が50%以上である、ポリ(3-ヒドロキシアルカノエート)粉体。
重量平均分子量保持率(%)=(160℃で20分間加熱した後のP3HAの重量平均分子量/160℃で20分間加熱する前のP3HAの重量平均分子量)×100 ・・・(1) - 重量平均分子量(Mw)と数平均分子量(Mn)との比(Mw/Mn)が、1.0~3.1である、請求項8に記載のポリ(3-ヒドロキシアルカノエート)粉体。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180076760.9A CN116547339A (zh) | 2020-11-24 | 2021-10-06 | 聚(3-羟基烷酸酯)的制造方法 |
US18/252,131 US20240010789A1 (en) | 2020-11-24 | 2021-10-06 | Poly(3-hydroxyalkanoate) production method |
EP21897508.4A EP4253552A1 (en) | 2020-11-24 | 2021-10-06 | Poly(3-hydroxyalkanoate) production method |
JP2022565097A JPWO2022113530A1 (ja) | 2020-11-24 | 2021-10-06 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020194506 | 2020-11-24 | ||
JP2020-194506 | 2020-11-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022113530A1 true WO2022113530A1 (ja) | 2022-06-02 |
Family
ID=81755740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/036938 WO2022113530A1 (ja) | 2020-11-24 | 2021-10-06 | ポリ(3-ヒドロキシアルカノエート)の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240010789A1 (ja) |
EP (1) | EP4253552A1 (ja) |
JP (1) | JPWO2022113530A1 (ja) |
CN (1) | CN116547339A (ja) |
WO (1) | WO2022113530A1 (ja) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0593049A (ja) | 1991-09-17 | 1993-04-16 | Kanegafuchi Chem Ind Co Ltd | 共重合体およびその製造方法 |
WO2004065608A1 (ja) * | 2003-01-20 | 2004-08-05 | Kaneka Corporation | 微生物菌体からの高純度ポリヒドロキシアルカノエートの回収方法 |
WO2005049692A1 (ja) * | 2003-11-21 | 2005-06-02 | Kaneka Corporation | ポリヒドロキシアルカノエート結晶の製造方法 |
WO2005085461A1 (ja) * | 2004-03-04 | 2005-09-15 | Kaneka Corporation | 核酸の分解方法及びその用途 |
JP2007524345A (ja) * | 2003-12-19 | 2007-08-30 | 寧波天安生物材料有限公司 | バクテリア発酵液からポリ−β−ヒドロキシアルカノエート(PHAs)を直接分離、抽出及び精製する方法 |
WO2010116681A1 (ja) * | 2009-03-30 | 2010-10-14 | 株式会社カネカ | ポリヒドロキシアルカノエートの回収方法 |
WO2019142717A1 (ja) | 2018-01-16 | 2019-07-25 | 株式会社カネカ | 変異型ポリヒドロキシアルカン酸合成酵素、その遺伝子および形質転換体、並びに、ポリヒドロキシアルカン酸の製造方法 |
CN111019108A (zh) | 2020-01-07 | 2020-04-17 | 清华大学 | 一种提取并纯化聚羟基脂肪酸酯的方法 |
WO2020218565A1 (ja) * | 2019-04-26 | 2020-10-29 | 株式会社フューエンス | ポリヒドロキシアルカン酸及びその製造方法 |
-
2021
- 2021-10-06 EP EP21897508.4A patent/EP4253552A1/en active Pending
- 2021-10-06 CN CN202180076760.9A patent/CN116547339A/zh active Pending
- 2021-10-06 WO PCT/JP2021/036938 patent/WO2022113530A1/ja active Application Filing
- 2021-10-06 JP JP2022565097A patent/JPWO2022113530A1/ja active Pending
- 2021-10-06 US US18/252,131 patent/US20240010789A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0593049A (ja) | 1991-09-17 | 1993-04-16 | Kanegafuchi Chem Ind Co Ltd | 共重合体およびその製造方法 |
WO2004065608A1 (ja) * | 2003-01-20 | 2004-08-05 | Kaneka Corporation | 微生物菌体からの高純度ポリヒドロキシアルカノエートの回収方法 |
WO2005049692A1 (ja) * | 2003-11-21 | 2005-06-02 | Kaneka Corporation | ポリヒドロキシアルカノエート結晶の製造方法 |
JP2007524345A (ja) * | 2003-12-19 | 2007-08-30 | 寧波天安生物材料有限公司 | バクテリア発酵液からポリ−β−ヒドロキシアルカノエート(PHAs)を直接分離、抽出及び精製する方法 |
WO2005085461A1 (ja) * | 2004-03-04 | 2005-09-15 | Kaneka Corporation | 核酸の分解方法及びその用途 |
WO2010116681A1 (ja) * | 2009-03-30 | 2010-10-14 | 株式会社カネカ | ポリヒドロキシアルカノエートの回収方法 |
JP2012115145A (ja) | 2009-03-30 | 2012-06-21 | Kaneka Corp | ポリヒドロキシアルカノエートの回収方法 |
WO2019142717A1 (ja) | 2018-01-16 | 2019-07-25 | 株式会社カネカ | 変異型ポリヒドロキシアルカン酸合成酵素、その遺伝子および形質転換体、並びに、ポリヒドロキシアルカン酸の製造方法 |
WO2020218565A1 (ja) * | 2019-04-26 | 2020-10-29 | 株式会社フューエンス | ポリヒドロキシアルカン酸及びその製造方法 |
CN111019108A (zh) | 2020-01-07 | 2020-04-17 | 清华大学 | 一种提取并纯化聚羟基脂肪酸酯的方法 |
Non-Patent Citations (1)
Title |
---|
JIANG YANG, MIKOVA GIZELA, KLEEREBEZEM ROBBERT, VAN DER WIELEN LUUK AM, CUELLAR MARIA C: "Feasibility study of an alkaline-based chemical treatment for the purification of polyhydroxybutyrate produced by a mixed enriched culture", AMB EXPRESS, vol. 5, no. 1, 1 December 2015 (2015-12-01), XP055933580, DOI: 10.1186/s13568-015-0096-5 * |
Also Published As
Publication number | Publication date |
---|---|
CN116547339A (zh) | 2023-08-04 |
US20240010789A1 (en) | 2024-01-11 |
JPWO2022113530A1 (ja) | 2022-06-02 |
EP4253552A1 (en) | 2023-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2366794B1 (en) | Method for producing poly-3-hydroxyalkanoate and agglomerate of poly-3-hydroxyalkanoate | |
CN110475868B (zh) | 聚羟基烷酸酯粒子及其水分散液 | |
WO2010116681A1 (ja) | ポリヒドロキシアルカノエートの回収方法 | |
CN109843985B (zh) | 聚羟基链烷酸酯的制造方法 | |
JPWO2004065608A1 (ja) | 微生物菌体からの高純度ポリヒドロキシアルカノエートの回収方法 | |
WO2021251049A1 (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
JP7209434B2 (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
JP2019097518A (ja) | ポリヒドロキシアルカノエート分散液の製造方法 | |
JPWO2005085461A1 (ja) | 核酸の分解方法及びその用途 | |
WO2022113530A1 (ja) | ポリ(3-ヒドロキシアルカノエート)の製造方法 | |
JPWO2010067541A1 (ja) | ポリ−3−ヒドロキシアルカン酸の生産方法 | |
WO2022091685A1 (ja) | ポリヒドロキシ酪酸共重合体の製造方法およびその利用 | |
WO2023037710A1 (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
JP6864585B2 (ja) | ポリヒドロキシアルカノエートの製造方法 | |
JP2021195470A (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
WO2024029514A1 (ja) | ポリヒドロキシアルカノエートの製造方法およびその利用 | |
WO2023021878A1 (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
WO2023085374A1 (ja) | ポリヒドロキシアルカン酸の製造方法 | |
JP2024037032A (ja) | ポリヒドロキシ酪酸共重合体の製造方法およびポリヒドロキシ酪酸共重合体粉体 | |
WO2024157882A1 (ja) | ポリヒドロキシアルカン酸の製造方法 | |
Kosseva et al. | Recovery of Polyhydroxyalkanoates from microbial biomass | |
JP2024028034A (ja) | ポリヒドロキシアルカン酸の製造方法およびその利用 | |
JP2023086317A (ja) | ポリヒドロキシアルカン酸粒子およびその製造方法 | |
CN117881717A (zh) | 聚羟基烷酸酯的制造方法及其利用 | |
Kosseva et al. | 6 Recovery of |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21897508 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18252131 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022565097 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180076760.9 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021897508 Country of ref document: EP Effective date: 20230626 |